Loading clinical trials...
Loading clinical trials...
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 (Umbralisib) in Patients With Chronic Lymphocytic Leukemia (CLL) Who Are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Conditions
Interventions
Umbralisib
Locations
15
United States
TG Therapeutics Investigational Trial Site
Huntsville, Alabama, United States
TG Therapeutics Investigational Trial Site
Washington D.C., District of Columbia, United States
TG Therapeutics Investigational Trial Site
Fort Myers, Florida, United States
TG Therapeutics Investigational Trial Site
St. Petersburg, Florida, United States
TG Therapeutics Investigational Trial Site
Kansas City, Missouri, United States
TG Therapeutics Investigational Trial Site
Lebanon, New Hampshire, United States
Start Date
April 21, 2016
Primary Completion Date
June 10, 2021
Completion Date
June 10, 2021
Last Updated
July 3, 2024
NCT06846671
NCT07218341
NCT06548152
NCT07030400
NCT05006716
NCT07277231
Lead Sponsor
TG Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions